image
Healthcare - Biotechnology - OTC - US
$ 0.0322
0 %
$ 110 K
Market Cap
0.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCON stock under the worst case scenario is HIDDEN Compared to the current market price of 0.0322 USD, TRACON Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCON stock under the base case scenario is HIDDEN Compared to the current market price of 0.0322 USD, TRACON Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCON stock under the best case scenario is HIDDEN Compared to the current market price of 0.0322 USD, TRACON Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TCON

image
$0.1$0.1$0.1$0.1$0.1$0.1$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.0$0.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
12 M REVENUE
0.00%
-6.9 M OPERATING INCOME
75.27%
-3.59 M NET INCOME
87.68%
3.68 M OPERATING CASH FLOW
114.01%
0 INVESTING CASH FLOW
100.00%
-12.5 M FINANCING CASH FLOW
-63.70%
55 K REVENUE
-45.00%
-2.91 M OPERATING INCOME
9.34%
-2.84 M NET INCOME
10.39%
-2.77 M OPERATING CASH FLOW
-8.89%
0 INVESTING CASH FLOW
0.00%
1.15 M FINANCING CASH FLOW
-38.61%
Balance Sheet TRACON Pharmaceuticals, Inc.
image
Current Assets 9.09 M
Cash & Short-Term Investments 8.56 M
Receivables 0
Other Current Assets 526 K
Non-Current Assets 1.02 M
Long-Term Investments 0
PP&E 942 K
Other Non-Current Assets 73 K
84.75 %5.21 %9.32 %Total Assets$10.1m
Current Liabilities 10.2 M
Accounts Payable 2.54 M
Short-Term Debt 236 K
Other Current Liabilities 7.4 M
Non-Current Liabilities 732 K
Long-Term Debt 732 K
Other Non-Current Liabilities 0
23.31 %67.82 %6.71 %Total Liabilities$10.9m
EFFICIENCY
Earnings Waterfall TRACON Pharmaceuticals, Inc.
image
Revenue 12 M
Cost Of Revenue 14 K
Gross Profit 12 M
Operating Expenses 18.9 M
Operating Income -6.9 M
Other Expenses -3.31 M
Net Income -3.59 M
14m14m12m12m10m10m8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)12m(14k)12m(19m)(7m)3m(4m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
99.88% GROSS MARGIN
99.88%
-57.27% OPERATING MARGIN
-57.27%
-29.79% NET MARGIN
-29.79%
443.51% ROE
443.51%
-35.51% ROA
-35.51%
-4338.36% ROIC
-4338.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TRACON Pharmaceuticals, Inc.
image
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -3.59 M
Depreciation & Amortization 14 K
Capital Expenditures 0
Stock-Based Compensation 1.97 M
Change in Working Capital -761 K
Others 6.69 M
Free Cash Flow 3.68 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TRACON Pharmaceuticals, Inc.
image
TCON has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership TRACON Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
TRACON Pharmaceuticals Announces it Will Wind Down Operations SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. globenewswire.com - 9 months ago
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy globenewswire.com - 10 months ago
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Charles Theuer - President & CEO Scott Brown - CFO Conference Call Participants Matthew Venezia - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all callers are in a listen-only mode. seekingalpha.com - 11 months ago
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. globenewswire.com - 11 months ago
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. globenewswire.com - 11 months ago
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential. investorplace.com - 1 year ago
TRACON Pharmaceuticals Announces Reverse Stock Split SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the Board) to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of one-for-five to one-for-twenty, the Company's Board today approved a reverse stock split of the Company's common stock at a ratio of one-for-twenty. globenewswire.com - 1 year ago
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript seekingalpha.com - 1 year ago
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. globenewswire.com - 1 year ago
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. globenewswire.com - 1 year ago
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ongoing pivotal Phase 2 ENVASARC trial has enrolled more than 70 of the 80 planned patients in Cohort C of single agent envafolimab treatment at a dose of 600 mg subQ every three weeks. Additional safety and efficacy data were reviewed for 46 patients enrolled into cohort C who were the subject of the September independent data monitoring committee (IDMC) review. globenewswire.com - 1 year ago
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today? Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million. investorplace.com - 1 year ago
8. Profile Summary

TRACON Pharmaceuticals, Inc. TCON

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 110 K
Dividend Yield 0.00%
Description TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Contact 4350 La Jolla Village Drive, San Diego, CA, 92122 https://www.traconpharma.com
IPO Date Jan. 30, 2015
Employees 17
Officers Mr. Ya Huang Executive Director of Statistical Programming Dr. James L. Freddo M.D. Chief Medical Officer Mr. Craig R. Jalbert CIRA Chief Executive Officer, President, Treasurer, Secretary & Director